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A formalized, multidisciplinary approach for patients with
placenta accreta spectrum may decrease the risk of maternal
morbidity, including blood loss, transfusion, and ICU admission.

HYPOTHESIS

Women requiring a peripartum hysterectomy have risk factors and outcomes that differ based on the circumstances of
care and management (unplanned hysterectomy, planned without a multidisciplinary approach and planned with a
multidisciplinary approach).

OBJECTIVES

• To determine the impact of a formalized, multidisciplinary Placenta Accreta Spectrum Program (PASP) on maternal and
neonatal outcomes for pregnancies complicated by placenta accreta spectrum.
• To identify whether having a multidisciplinary approach for the antepartum, intraoperative, and postpartum management
of women undergoing cesarean hysterectomy affects maternal and fetal outcomes.

STUDY DESIGN

• A registered database of all women who underwent a peripartum hysterectomy at a Level IV Regional Perinatal Health Care
Center from December 1, 2007 to June 30, 2019 was created.
• In 2012, a monthly meeting to create a multidisciplinary management plan for all patients with suspected placenta accreta
was implemented (PASP).
• We conducted a retrospective cohort study of all women from our database who underwent a cesarean hysterectomy and
compared maternal and neonatal outcomes of women discussed at PASP compared with those that were not discussed in
the program.
• Primary outcomes were maternal transfusion and NICU admission.
• Secondary outcomes included EBL, planned (vs unplanned) procedure, prenatal diagnosis of accreta spectrum, maternal
and neonatal outcomes, and surgical complications.
• Data were analyzed using univariate and multivariable techniques

Table 1. Baseline characteristics of women with peripartum hysterectomy for
placenta accreta spectrum

Table 2. Select maternal and neonatal outcomes in pregnancies with placenta
accreta spectrum

No PASP N = 30

PASP N = 41

p value

35 (31, 38)

34 (30, 38)

0.62

Gestational age at delivery (weeks) a

Caucasian, n (%)

17 (56.7)

24 (58.5)

0.84

Antenatal corticosteroids, n (%)

Multiparity, n (%)

29 (96.7)

40 (97.6)

0.82

Circumstances of peripartum hysterectomy, n (%)

Government insurance, n (%)

9 (30.0)

20 (48.8)

0.20

Planned*

29.1 (23.4, 36.8)

29.1 (25, 32.7)

0.85

Unplanned

BMI ≥ 40, n (%)

2 (6.7)

5 (12.2)

0.44

Preoperative prophylactic procedures, n (%)

Smoking, n (%)

4 (13.3)

6 (14.6)

0.75

Maternal age at delivery (years)a

Body mass index (kg/m2)

a

Number of previous cesareans, n (%)

71 women had peripartum hysterectomy, of which 41 were discussed in PASP. 15 women who delivered after implementation
of PASP did not participate, due to unplanned preterm delivery, transport from another hospital, or undiagnosed accreta. The
figure demonstrates an example of the template used for women discussed in PASP. Table 1 details the baseline characteristics
of women who underwent peripartum hysterectomy for placenta accreta spectrum. Table 2 describes the select maternal and
neonatal outcomes in pregnancies with placenta accreta spectrum

The PASP group was more likely to have the following characteristics and outcomes:
lower rates of transfusion

46.7% no PASP vs. 100% PASP, p<0.001
86.7% no PASP vs. 39.0% PASP, p<0.001

No PASP N = 30

PASP N = 41

p value

36.2 (31.3, 38.5)

34.4 (34.0, 35.0)

0.02

13 (43.3)

34 (82.9)

<0.001

6 (20.0)

24 (58.5)

24 (80.0)

17 (41.5)

Pelvic vasculature occlusion catheters

5 (16.7)

35 (85.4)

<0.001

Ureteric stent placement

8 (26.7)

37 (90.2)

<0.001

Articulating mechanical stapler for hysterotomy

1 (3.3)

8 (19.5)

0.04

Low transverse

10 (33.3)

0 (0)

12 (40.0)

34 (82.9)

#

11 (36.7)

5 (12.2)

1

9 (30.0)

7 (17.1)

2

6 (20.0)

12 (29.3)

3

3 (10.0)

11 (26.8)

Vertical/classical

≥4

1 (3.3)

6 (14.6)

Other

1 (3.3)

7 (17.1)

Previous D&C, n (%)

9 (30.0)

17 (41.5)

0.32

Not specified

7 (23.3)

0 (0)

Other previous uterine surgery, n (%)

23 (76.7)

41 (100.0)

0.001

Total operative time (minutes) a

181.5 (156.0, 232.0)

289.0 (242.0, 340.0)

<0.001

Previous hemorrhage, n (%)

7 (23.3)

3 (7.3)

0.05

Estimated blood loss (milliliters)a

2450 (1200, 4000)

800 (600, 1500)

0.003

Assisted reproductive conception, n (%)

6 (20.0)

3 (7.3)

0.11

26 (86.7)

16 (39.0)

<0.001

Pregestational diabetes, n (%)

2 (6.7)

0 (0)

0.09

Ureteral injury

1 (3.3)

1 (2.4)

0.96

Bladder injury

6 (20.0)

8 (19.5)

0.96

18 (60.0)

14 (34.1)

0.03

1 (1, 2)

1 (1, 1)

0.02

0.02

Transfusion of any blood products, n (%)

4 (13.3)

4 (9.8)

0.64

higher NICU admission rate

53.6% no PASP vs. 85.4% PASP, p=0.004

Chronic hypertension, n (%)

0 (0)

1 (2.4)

0.39

lower median blood loss

2450 ml no PASP vs. 800 ml PASP, p=0.003

Prenatal diagnosis of placenta accreta spectrum, n (%)

14 (46.7)

41 (100.0)

<0.001

27.7 (21.3, 34.4)

23.5 (20.0, 29.3)

0.08

Neonatal birthweight (grams) a

Placenta previa, n (%)

14 (46.7)

34 (82.9)

0.001

Neonatal intensive care admission, n (%)

Prenatal magnetic resonance imaging, n (%)

3 (10.0)

34 (82.9)

<0.001
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Gestational age at diagnosis (weeks) a

Data expressed as median (interquartile range)

a

<0.001

Surgical injury, n (%)

Gestational diabetes, n (%)

Surgical time was likely increased due to more frequent use of routine embolization and ureteral stents in the PASP group.
After adjustment of potential confounders - planned (vs. unplanned) delivery and delivery after implementation of PASP in
2012, which may have influenced management of all women regardless of PASP status, PASP participation was still
associated with a reduction in transfusion rate [AOR 0.14 (0.03,0.74), p=0.02].

ISSUES

SURGICAL PLAN

CARE TEAM

on (date)
• Anesthesia – epidural to general
anesthesia for hysterectomy –
T4 level with anesthesia – to keep
catheter for post-op pain control
• Patient position – Low lithotomy in
Allen stirrups
• Urology – Cystoscopy with placement
of ureteral catheters – 3-way foley
to be placed following ureteral
catheter placement
• Equipment
• 5F open-ended ureteral catheters x 2
• Sensor wire
• 18F and 20F 3-way foley catheter
• Rigid cystoscopy tray
• IR – to place femoral catheters
• Equipment – IR will bring cart
• C-section (Primary surgeon – (name);
assisted by (name and specialty)

• Placenta accreta
• Obstetrics

• GYN oncology
• Interventional Radiology

ANTENATAL

• Admission for symptoms
• BMZ around 32 weeks (pending MFM

recommendations)
• Consults
• GYN oncology –
• Interventional radiology –
• Anesthesia • NICU • MRI of pelvis WITHOUT gadolinium
• Optimize Hemoglobin (>11)
• Type and cross for 4 units
• Delivery in the Main OR at 34-35 weeks

• To be scheduled in the Main OR

• Midline vertical incision
• Anterior-fundal incision with goal of

staying away from the placenta
• Baby passed to NICU – FOB to go
with NICU to nursery
• Designated person to communicate with
the family – Peri-op RN
• IR – Embolization
• Equipment – IR will bring cart
• C-hysterectomy (Primary surgeon –
GYN oncology with 1st assistant (name)
and 2nd assist by (name)
• Equipment
• GYN oncology tray/Code crimson tray
• Glassman clamps
• Bookwalter retractor/Omni retractor
• LigaSure Impact
• MICU/SICU for post-op care
• Epidural catheter to be kept in place
for post-op pain control

Uterine incision, n (%)

60% no PASP vs. 34.2% PASP, p=0.03

181.5 minutes no PASP vs. 289 minutes PASP, p<0.001

0.001

0

lower maternal ICU admission

longer median surgical time

Abnormal Placentation Template (plan meeting for around 28 weeks)
Plan of Care for
MRN:
EDC:

• High Risk

RESULTS

prenatal diagnosis of previa or accreta spectrum

TEMPLATE USED FOR MULTIDISCIPLINARY PLAN FOR PASP

Maternal intensive care admission, n (%)
Number of days in ICUa

2787.5 (2130, 3235) 2342.5 (2095, 2642.5)
15 (50.0)

35 (85.4)

0.03
0.004

CONCLUSION

• A formalized, multidisciplinary approach for patients with placenta accreta spectrum may decrease the risk of maternal
morbidity, including blood loss, transfusion, and ICU admission. In our study population, the discussion of women under the
PASP program was associated with a reduction in transfusion rate [AOR 0.14 (0.03,0.74), p=0.02] after controlling for
planned (vs. unplanned) delivery and whether the delivery took place after implementation of PASP in 2012.
• Surgical time was longer for women managed under the PASP program. This finding is likely explained by the more frequent
use of prophylactic pelvic vasculature occlusion and ureteric stent placement in the PASP group.
• The creation of the program has led to the standardization in the management of patients with placenta accreta spectrum
when prenatally diagnosed and has likely led to an increased awareness of the need for prenatal imaging, high index of
suspicion while imaging women with known risk factors for placental invasion, and increased use of interdisciplinary
services when managing women with risk factors. Additional data regarding the benefit of prenatal magnetic resonance
imaging, prophylactic pelvic vasculature occlusion and ureteric stent placement are needed.
• The care of women with placenta accreta spectrum must take place using a multidisciplinary approach in a center capable
of managing surgically complicated cases.

Data expressed as median (interquartile range)
*Planned procedures took place as scheduled due to diagnosis of placenta accreta spectrum
#
Unplanned procedures were performed earlier than originally scheduled due to bleeding/labor or due to undiagnosed
placenta accreta spectrum
a
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